January 27, 2026
Roche’s CT-388 Obesity Drug Achieves 22.5% Weight Loss in Phase II, Advances to Phase III
Roche; CT-388; obesity drug; GLP-1/GIP; Phase II; Phase III; weight loss
SBA Defends 8(a) Program Reforms Amid Constitutional Challenges and Increased Scrutiny in 2026
8(a) program; SBA; business practices; constitutional challenges; Trump Administration; social disadvantage
Sarepta Therapeutics Reports Positive Three-Year EMBARK Data for Elevidys in Duchenne Amid Past Safety Concerns
Sarepta; Elevidys; Duchenne muscular dystrophy; EMBARK trial; three-year data; gene therapy; patient deaths
AsedaSciences and GenEvolutioN Announce Sales & Marketing Agreement to Integrate Genotoxicity Screen into 3RnD Platform
AsedaSciences; GenEvolutioN; 3RnD; genotoxicity screen; sales agreement; New Approach Methods; NAMs
QIAGEN Appoints Mark Stevenson to Supervisory Board
QIAGEN; Mark Stevenson; Supervisory Board; appointment; life sciences
AsedaSciences and Clyde Biosciences Announce Commercial Agreement to Integrate Human-Relevant Cardiotoxicity Screening
AsedaSciences; Clyde Biosciences; 3RnD platform; CellOPTIQ; cardiotoxicity screening; New Approach Methods; NAMs
Narmafotinib Large-Scale Manufacture Complete by Amplia Therapeutics
narmafotinib; Amplia Therapeutics; large-scale manufacture; Phase 3 readiness; pancreatic cancer; GMP